Andrew J. Donnelly, PharmD, MBA, FASHP

Burnout, drug and technician shortages, home care, remote work, and telehealth continue to trend

Institutions are replacing innovator biologics with their biosimilars, often to take advantage of the financial benefits.

Drug shortages and rising prices remain a major issue, with drug pricing legislation on a national level going nowhere fast, and a new gene therapy becoming the most expensive drug approved by the FDA. The opioid epidemic continues to hold the attention of health care providers and organizations, and burnout is increasingly recognized as a problem that needs addressing.

The United States is on the cusp of seeing significantly more activity related to these products.